Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration

M. Barrecheguren, K. O'Hara, M. Wilkens, J. Boyd, E. Kolda, B. Lara, J. Chorostowska-Wynimko, I. Ferrarotti, J. Chlumský, C. Clarenbach, T. Greulich, M. Miravitlles, M. Sucena

. 2020 ; 6 (4) : . [pub] 20201221

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010209

α1-antitrypsin deficiency (AATD) is a rare and under-recognised genetic condition. Owing to its low prevalence, international initiatives are key for conducting high-quality research in the field. From July 2018 to December 2019, the European Alpha-1 Research Collaboration (EARCO) developed and conducted two surveys, one for healthcare providers and one for patients and caregivers, aiming to identify research priorities and barriers in access to treatment for AATD. A survey on 164 research questions was electronically sent to 230 AATD experts in Europe, and 94 completed surveys from 24 countries were received. The top research areas identified by healthcare providers were causes of variable progression and poor outcomes, improvement in diagnosis, initiation and optimal dosing of augmentation therapy and effectiveness of self-management interventions. During the same period, 438 surveys were completed by patients and caregivers from 26 countries. The top research areas identified were improving knowledge about AATD, in particular among general practitioners, access to AATD specialised centres and access to reliable, easy to understand information about living with AATD. Regarding barriers to treatment, participants from countries where augmentation therapy was reimbursed prioritised improving knowledge in AATD, while respondents in non-reimbursed countries regarded access to AATD augmentation therapy and to specialised centres as the most relevant. The main research and management priorities identified by healthcare providers and patients included understanding the natural history of AATD, improving information to physicians, improving access to specialised reference centres, personalising treatment and having equal opportunities for access to existing therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010209
003      
CZ-PrNML
005      
20210610133345.0
007      
ta
008      
210413s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1183/23120541.00523-2020 $2 doi
035    __
$a (PubMed)33447613
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Barrecheguren, Miriam $u Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
245    10
$a Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration / $c M. Barrecheguren, K. O'Hara, M. Wilkens, J. Boyd, E. Kolda, B. Lara, J. Chorostowska-Wynimko, I. Ferrarotti, J. Chlumský, C. Clarenbach, T. Greulich, M. Miravitlles, M. Sucena
520    9_
$a α1-antitrypsin deficiency (AATD) is a rare and under-recognised genetic condition. Owing to its low prevalence, international initiatives are key for conducting high-quality research in the field. From July 2018 to December 2019, the European Alpha-1 Research Collaboration (EARCO) developed and conducted two surveys, one for healthcare providers and one for patients and caregivers, aiming to identify research priorities and barriers in access to treatment for AATD. A survey on 164 research questions was electronically sent to 230 AATD experts in Europe, and 94 completed surveys from 24 countries were received. The top research areas identified by healthcare providers were causes of variable progression and poor outcomes, improvement in diagnosis, initiation and optimal dosing of augmentation therapy and effectiveness of self-management interventions. During the same period, 438 surveys were completed by patients and caregivers from 26 countries. The top research areas identified were improving knowledge about AATD, in particular among general practitioners, access to AATD specialised centres and access to reliable, easy to understand information about living with AATD. Regarding barriers to treatment, participants from countries where augmentation therapy was reimbursed prioritised improving knowledge in AATD, while respondents in non-reimbursed countries regarded access to AATD augmentation therapy and to specialised centres as the most relevant. The main research and management priorities identified by healthcare providers and patients included understanding the natural history of AATD, improving information to physicians, improving access to specialised reference centres, personalising treatment and having equal opportunities for access to existing therapies.
655    _2
$a časopisecké články $7 D016428
700    1_
$a O'Hara, Karen $u Alpha-1 UK Support Group, Droitwich, UK
700    1_
$a Wilkens, Marion $u Alpha1 Deutschland e.V, Gernsheim, Germany
700    1_
$a Boyd, Jeanette $u European Lung Foundation, Sheffield, UK
700    1_
$a Kolda, Ewa $u Dept of Respiratory Medicine, Allergology and Pulmonary Oncology, Poznań University of Medical Sciences, Poznan, Poland
700    1_
$a Lara, Beatriz $u Dept of Respiratory Medicine, University Hospitals of Coventry and Warwickshire, Coventry, UK
700    1_
$a Chorostowska-Wynimko, Joanna $u Dept of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
700    1_
$a Ferrarotti, Ilaria $u Dept of Internal Medicine and Therapeutics, Pneumology Unit, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
700    1_
$a Chlumský, Jan $u Dept of Pneumology, Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Clarenbach, Christian $u Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland
700    1_
$a Greulich, Timm $u Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-University, Member of the German Centre for Lung Research (DZL), Marburg, Germany
700    1_
$a Miravitlles, Marc $u Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
700    1_
$a Sucena, Maria $u Pulmonology Dept, Centro Hospitalar do Porto, Porto, Portugal
773    0_
$w MED00198703 $t ERJ open research $x 2312-0541 $g Roč. 6, č. 4 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33447613 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210610133344 $b ABA008
999    __
$a ind $b bmc $g 1649724 $s 1130585
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 6 $c 4 $e 20201221 $i 2312-0541 $m ERJ open research $n ERJ Open Res $x MED00198703
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace